270 related articles for article (PubMed ID: 25971340)
1. Do we need a vaccine against chikungunya?
Rezza G
Pathog Glob Health; 2015 Jun; 109(4):170-3. PubMed ID: 25971340
[TBL] [Abstract][Full Text] [Related]
2. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
[TBL] [Abstract][Full Text] [Related]
3. Development of Vaccines for Chikungunya Fever.
Erasmus JH; Rossi SL; Weaver SC
J Infect Dis; 2016 Dec; 214(suppl 5):S488-S496. PubMed ID: 27920179
[TBL] [Abstract][Full Text] [Related]
4. A chikungunya fever vaccine utilizing an insect-specific virus platform.
Erasmus JH; Auguste AJ; Kaelber JT; Luo H; Rossi SL; Fenton K; Leal G; Kim DY; Chiu W; Wang T; Frolov I; Nasar F; Weaver SC
Nat Med; 2017 Feb; 23(2):192-199. PubMed ID: 27991917
[TBL] [Abstract][Full Text] [Related]
5. Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus.
Roques P; Ljungberg K; Kümmerer BM; Gosse L; Dereuddre-Bosquet N; Tchitchek N; Hallengärd D; García-Arriaza J; Meinke A; Esteban M; Merits A; Le Grand R; Liljeström P
JCI Insight; 2017 Mar; 2(6):e83527. PubMed ID: 28352649
[TBL] [Abstract][Full Text] [Related]
6. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
Front Immunol; 2021; 12():655743. PubMed ID: 33868299
[TBL] [Abstract][Full Text] [Related]
7. Production of a Chikungunya Vaccine Using a CHO Cell and Attenuated Viral-Based Platform Technology.
Eldi P; Cooper TH; Liu L; Prow NA; Diener KR; Howley PM; Suhrbier A; Hayball JD
Mol Ther; 2017 Oct; 25(10):2332-2344. PubMed ID: 28720468
[TBL] [Abstract][Full Text] [Related]
8. Therapeutics and vaccines against chikungunya virus.
Ahola T; Couderc T; Ng LF; Hallengärd D; Powers A; Lecuit M; Esteban M; Merits A; Roques P; Liljeström P
Vector Borne Zoonotic Dis; 2015 Apr; 15(4):250-7. PubMed ID: 25897811
[TBL] [Abstract][Full Text] [Related]
9. Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose.
Abeyratne E; Tharmarajah K; Freitas JR; Mostafavi H; Mahalingam S; Zaid A; Zaman M; Taylor A
Front Immunol; 2020; 11():304. PubMed ID: 32194557
[TBL] [Abstract][Full Text] [Related]
10. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice.
Hallengärd D; Kakoulidou M; Lulla A; Kümmerer BM; Johansson DX; Mutso M; Lulla V; Fazakerley JK; Roques P; Le Grand R; Merits A; Liljeström P
J Virol; 2014 Mar; 88(5):2858-66. PubMed ID: 24371047
[TBL] [Abstract][Full Text] [Related]
11. Regulatory considerations in development of vaccines to prevent disease caused by Chikungunya virus.
Yang S; Fink D; Hulse A; Pratt RD
Vaccine; 2017 Sep; 35(37):4851-4858. PubMed ID: 28760614
[TBL] [Abstract][Full Text] [Related]
12. Recent development in the strategies projected for chikungunya vaccine in humans.
Goyal M; Chauhan A; Goyal V; Jaiswal N; Singh S; Singh M
Drug Des Devel Ther; 2018; 12():4195-4206. PubMed ID: 30573950
[TBL] [Abstract][Full Text] [Related]
13. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus.
Brandler S; Ruffié C; Combredet C; Brault JB; Najburg V; Prevost MC; Habel A; Tauber E; Desprès P; Tangy F
Vaccine; 2013 Aug; 31(36):3718-25. PubMed ID: 23742993
[TBL] [Abstract][Full Text] [Related]
14. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits.
Metz SW; Martina BE; van den Doel P; Geertsema C; Osterhaus AD; Vlak JM; Pijlman GP
Vaccine; 2013 Dec; 31(51):6092-6. PubMed ID: 24099875
[TBL] [Abstract][Full Text] [Related]
15. Chikungunya Virus Vaccines: Viral Vector-Based Approaches.
Ramsauer K; Tangy F
J Infect Dis; 2016 Dec; 214(suppl 5):S500-S505. PubMed ID: 27920181
[TBL] [Abstract][Full Text] [Related]
16. Infectious Chikungunya Virus (CHIKV) with a Complete Capsid Deletion: a New Approach for a CHIKV Vaccine.
Zhang YN; Deng CL; Li JQ; Li N; Zhang QY; Ye HQ; Yuan ZM; Zhang B
J Virol; 2019 Aug; 93(15):. PubMed ID: 31092567
[TBL] [Abstract][Full Text] [Related]
17. Amid Paraguay Chikungunya Outbreak, Vaccine Candidate Safe, Immunogenic.
Harris E
JAMA; 2023 Jul; 330(2):111. PubMed ID: 37342059
[No Abstract] [Full Text] [Related]
18. Chikungunya vaccines in development.
Schwameis M; Buchtele N; Wadowski PP; Schoergenhofer C; Jilma B
Hum Vaccin Immunother; 2016 Mar; 12(3):716-31. PubMed ID: 26554522
[TBL] [Abstract][Full Text] [Related]
19. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]